Oncolytics Biotech® to Participate in BIO Investor Forum Digital

About Oncolytics Biotech Inc. About Oncolytics Biotech Inc. Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved...

SAN DIEGO, 07/10/2020 (informazione.news - comunicati stampa - scienza e tecnologia)

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.

Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.

Logo: https://mma.prnewswire.com/media/1064079/Oncolytics_Logo.jpg

 

Chief Financial Officer

403.670.7658

KLook@oncolytics.ca  

LifeSci Advisors

917.679.9282

tim@lifesciadvisors.com